
Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS
Key Takeaways
- A 255-patient, 15-site China trial randomizes ALS adults to CB03-154 5/10/15 mg QD or placebo for 39 weeks, with ALSFRS-R change at week 39 primary endpoint.
- Eligibility enriches for earlier, less advanced disease: revised El Escorial diagnosis, ≤24 months from symptom onset, and FVC >80% predicted, aiming to improve signal detection.
A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.
Zhimeng Biopharma has completed patient enrollment in a pivotal phase 2/3 trial testing CB03-154, an oral potassium channel opener, in people with amyotrophic lateral sclerosis (ALS), a disease that still lacks a therapy able to meaningfully reverse progression. The trial, conducted across multiple sites in China, will determine whether the drug's mechanism, designed to calm hyperexcitable motor neurons, can slow functional decline.1
The trial (NCT07082192) is a randomized, placebo-controlled, parallel-group study enrolling adults 18 to 65 years old with ALS diagnosed by revised El Escorial criteria, within 24 months of symptom onset, and with forced vital capacity above 80% of predicted.2 It enrolled 255 patients at 15 sites across China, randomized to 1 of 3 oral CB03-154 doses, 5 mg, 10 mg, or 15 mg once daily, or placebo, using a double-dummy design to preserve blinding across dose groups.1,2
Patients receive 39 weeks of double-blind treatment, with an optional 39-week open-label extension in which all participants receive CB03-154. The primary endpoint is change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) at week 39. Investigators are also tracking survival, need for long-term ventilatory support, lung function, depression symptoms, quality of life, and blood neurofilament light chain, an axonal injury biomarker. Fan Dongsheng, MD, PhD, who directs the neurology department at Peking University Third Hospital, is the trial's lead investigator.3
“The completion of patient enrollment for the pivotal phase 2/3 clinical trial of CB03-154 marks a strategically significant milestone for Zhimeng Biopharma,” Huanming Chen, PhD, founder and CEO of Zhimeng Biopharma, who also thanked the investigators, patients, and families involved. Topline results are expected in the third quarter of 2027; if they are positive, the company has said it plans to seek conditional approval in China.1
Mechanistically, CB03-154 opens KCNQ2/3 (Kv7.2/7.3) potassium channels, a target the company describes as designed with greater selectivity and stability than earlier molecules in the same class. The rationale rests on neuronal hyperexcitability, in which motor neurons fire more readily than normal, a feature observed in both ALS model systems and patients that is thought to contribute to neurodegeneration.
READ MORE:
That rationale was first tested clinically with ezogabine (retigabine), an earlier KCNQ2/3 opener that had been approved for epilepsy before being withdrawn from the market in 2017. A randomized trial of ezogabine in 65 patients with ALS, led by Brian J. Wainger, MD, PhD, of Massachusetts General Hospital, found that 900 mg/day increased cortical inhibition on a measure called short-interval intracortical inhibition by 53% versus placebo (P =.009) and reduced a marker of axonal excitability, the strength-duration time constant (P <.001), after 4 weeks at full dose.4
The trial found no significant change in ALSFRS-R, slow vital capacity, or muscle strength, which the investigators attributed to the short treatment period, and 26% to 30% of ezogabine-treated patients discontinued because of adverse events, compared with none on placebo.4 Ezogabine's epilepsy approval had already carried warnings for retinal pigment changes and skin discoloration, concerns the company says CB03-154 is unlikely to share because of its greater receptor selectivity.5
In preclinical studies, CB03-154 showed an ability to reduce hyperexcitability in motor neurons derived from ALS patient cells and, in a mouse model of ALS, improved motor function, extended survival, and increased nerve conduction velocity.3
A phase 1 trial in Australia (NCT05502549) gave single doses up to 30 mg and 14 days of dosing up to 20 mg/day to 56 healthy volunteers; the drug was generally well tolerated, with mild dizziness, sleepiness, and headache as the most common related effects, one moderate adverse event, and one brief EEG abnormality that resolved within a minute.3 A separate phase 1 trial in the United States (NCT05499260) completed dosing in 2023. The molecule, then designated CB03, received FDA orphan drug designation for ALS in October 2023.5
REFERENCES
1. Zhimeng Biopharma has completed the patients' enrollment of its investigational drug CB03-154 in the pivotal Phase 2/3 ALS clinical trial. News release. Zhimeng Biopharma. Published October 31, 2026. Accessed November 13, 2026. https://www.prnewswire.com/news-releases/zhimeng-biopharma-has-completed-the-patients-enrollment-of-its-investigational-drug-cb03-154-in-the-pivotal-phase-23-als-clinical-trial-302924801.html
2. A study to evaluate the efficacy and safety of different doses of CB03-154 in adult patients with amyotrophic lateral sclerosis (ALS). ClinicalTrials.gov identifier: NCT07082192. Accessed November 13, 2026. https://clinicaltrials.gov/study/NCT07082192
3. Zhimeng Biopharma's next-generation KCNQ2/3 potassium channel opener receives clinical trial approval for ALS Phase 2/3 study. News release. Zhimeng Biopharma. Published July 17, 2025. Accessed November 13, 2026. https://www.prnewswire.com/news-releases/zhimeng-biopharmas-next-generation-kcnq23-potassium-channel-opener-receives-clinical-trial-approval-for-als-phase-23-study-302500086.html
4. Wainger BJ, Macklin EA, Vucic S, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. Published online November 23, 2020. doi:10.1001/jamaneurol.2020.4300
5. Zhimeng Biopharma CB03 received orphan drug designation from the US FDA, a potassium ion channel opener for amyotrophic lateral sclerosis. News release. Zhimeng Biopharma. Published October 20, 2023. Accessed November 13, 2026. https://www.prnewswire.com/news-releases/zhimeng-biopharma-cb03-received-orphan-drug-designation-from-the-us-fda---a-potassium-ion-channel-opener-for-amyotrophic-lateral-sclerosis-301962939.html
Related to this article








